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Summary.-The Fractional Incorporation (FI) of [3H] thymidine ([3H] TdR) has been examined in small lung tumours after cyclophosphamide (CY) treatment in vivo and compared to the DNA specific activity (SA) at different times after treatment.
Fl was found to correlate with the incidence of labelled cells after treatment, whereas SA did not, due to the loss of DNA from drug-killed cells 72 h after treatment. The FT is independent of the precursor concentration in the tissue, and therefore may give a better index of DNA synthesis in irregularly perfused tissues than SA.
Following either CY or 60Co radiation treatment, the time necessary for FT to reach the pretreatment level is quite similar to the growth delay measured for the corresponding treatment in the Lewis lung or B16 tumours. A relationship between FT depression 45 h after treatment and growth delay has been established in the Lewis lung tumour, which would allow the prediction of growth delay induced by another agent to be made within 2 days of treatment.
ONE of the major problems associated with the development ofanticancer regimes or agents is that of quantification of tumour response. Ideally, after treatment, one would like to follow the change in the number of clonogenic cells present in the tumour, that is, the cells with the capacity to repopulate the tumour. However, at present, clonogenic assays are available for very few tumours, and such assays with primary human tumours present formidable difficulties. Change in tumour volume is one of the most commonly used measures, but it will often depend to an important extent on factors other, than clonogenic cell killing, in particular the rate of cell loss from the treated tumour (Bagshawe, 1968; Denekamp, 1972) . Interpretation of tumour volume change is particularly difficult when there is a difference in the rate of tumour growth before and after treatment.
Biochemical methods used to assess tumour response, most commonly based on the rate of incorporation of [3H] thymidine ([3H]TdR) or other labelled precursors into DNA, have many attractions ifthe data can be usefully interpreted. The parameter most commonly used as a measure of the rate of DNA synthesis has been the DNA specific activity (SA), that is, the amount of radioactivity incorporated per unit DNA. This measure has certain limitations when applied to studies in tissues after treatment with cytotoxic or other agents, since drug-induced changes in precursor pool sizes or the activities of polymerases or kinase enzymes may influence the uptake of labelled precursor into DNA in a manner that does not reflect the changes in the numbers of cells in the tissue which are engaged in DNA synthesis. SA measurement has further limitations when it is applied to tissues having irregular perfusion or a low proportion of cycling cells, since the precursor incorporation into DNA is proportional to the amount of the precursor reaching the tissue, and the SA is also dependent on the total DNA content of the sample, which includes contributions from nonccling cells (including those cells that have ceased to cvele due to drug-induced damage) as well as that from cveling cells.
Several clinical studies have shown a correlation between a decrease in thymidine labelling index and a positive clinical response, that is, a volume regression or a period of stasis in tumour growth, following chemotherapy (Skv-Peck, 1971 : Wolberg, 1971 WA-heeler, Dendy and Dawson, 1974: Murphv et al., 1975) . The aim of this paper is to examine whether data derived from the fractional incorporation technique described here can be related to the tumour growth delay following drug or radiation treatment. heavily irradiated cells (Hill and Stanley, 1975) (Threlfall and Taylor. 1969) . The acidsoluble RNA and DNA fractions were extracted in a total volume of 2 ml each. whereas for subcutaneous and intramuscular tumours the extraction volumes were 15 ml. DNA was assaved bv u.v. absorption at 260 nm. corrected for protein contamination (Lowry et al.. 1951) as described previouslv (Munro and Fleck, 1968) . Highlv polvmerized calf thyvmus DNA (Sigma Chemical Co.) was used for the preparation of standards, a solution containing 1 mg/ml giving an optical density of 27 (Bevan, Holiday and Johnson, 1955) .
For radiation treatment of the intramuscular tumours the animals were anaesthetized and irradiated with 6"Co y ravs at a dose rate of 50 rad/min. All areas of the body other than the tumour-bearing leg, were shielded with lead blocks during the treatment.
For growth delay studies subcutaneous tumours were treated at about 8 mm diameter, and were measured using Vernier calipers every 3 days. The tumour volume was calculated from the measurement of 2 perpendicular diameters using the formula:
The growth delay was taken as the increase in time for the treated tumours to grow to 4 times their treatment volume compared to the untreated controls.
Tumours used for autoradiographic studies (ARG) were fixed in formol saline, sectioned (6 ,um) and washed overnight with water followed by HCI (5N) at room temperature to remove any labelled nucleotides (Bianchi. Crathorn and Shooter, 1962) . Sections were dipped in photographic emulsion (Wlford K5) before being exposed for 2-4 weeks, and were stained with haematoxylin and eosin. In experiments in which the integrity of tumour cell nuclei was examined, tissues were fixed in methanol-acetic acid (3:1), stained with Giemsa and squashed on a microscope slide.
The radioactivity due to 3H was measured in an automatic liquid scintillation spectrometer (Intertechnique Ltd., Model SL40), using an emulsion scintillant composed of 7 volumes of 0-6 (w/v) butyl-PBD in tloluene and 3 volumes of Tergitol TP9 (Taylor, Tew and Jones, 1976) Where the distribution of 3H was studied in subcutaneous tumours, these were frozen and sectioned at 1-mm intervals (cross-sections) and each crosssection was subdivided. The radioactivity of each 1-2 mm square was measured.
RESULTS
Following CY (300 mg/kg) the DNA SA incidence of labelled cells per field and thymidine Fl were depressed at 24 and 48h after treatment in pulmonary tumours, but SA increased to greater than the control level at 72 h (Fig. 1) . The SA data indicate an increase in the rate of DNA synthesis or in the number of cells in " S-phase " at this time, although the number of cells per microscope field that were labelled remained constant between 48 and 72 h, as did the grain count per cell.
There was an 80% fall in DNA/mg between 48 and 72 h in these pulmonary tumours, which corresponds to a loss of nuclear integrity, observed in tumour squashes at this time after tumour treatment (Fig.  2) .
For the assessment of the effects of cytotoxic agents on cell proliferation, using the rate of DNA synthesis as a marker, it is desirable to have an index which is independent of the total DNA content of the tissue sample and the absolute level of precursor uptake. The data in Table I show that for a given tissue Fl is constant over a greater than ten-fold range of
[3H]TdR dosage, whereas SA rises with increasing dose (Cleaver, 1967 (Fig. 3) . The detailed distribution of (Table H) . The effect of local 60Co irradiation of intramuscular Lewis lung tumours is Fig. 6 , and the predicted recovery time was found to be similar to the growth delay measured for the corresponding dose level (Table LLL) .
Limited studies using subcutaneous B 16 tumours have shown that FL is depressed quite considerably and recovers in a dose-dependent fashion after CY administration (Fig. 7) .06 similar to the growth delay caused by the corresponding treatment. It is probably fortuitous that the two measurements are so similar, for where the tumour regrows at a different rate from the control (as does the B16 tumour following CY) the growth delay is continually changing as growth proceeds. For example, where the post-treatment doubling time is slower than before treatment, the growth delay will continue to increase with time after treatment. By measuring growth delay at a time when the treated tumour has reached 4 times its treatment volume, a sufficient period has been allowed for most of the drug-induced debris to be removed. However, where little cell killing has been achieved, for example less than one order of cell killing, then it is probable that regrowth will occur before the debris has been removed. Consequently the growth delay may be less than that expected for the level of cell killing due to repopulating cells " building " on to debris.
It would appear that the recovery curve for [3H]TdR Fl in these tumours is a composite function determined by the rate of repopulation of the tumour by clonogenic cells, and the rate at which damaged cells cease to cycle.
In these 2 rodent tumours it would appear that depression of Fl within a few days of treatment may be related to the tumour growth delay. Where such a relationship has been established for the tumour line, it may be possible to predict the growth delay corresponding to Fl depression produced by another agent. Such an assay would permit the rapid assessment of agents used singly or in combination in tumours such as human tumour xenografts which are not suitable for in vitro procedures.
